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Abstract
The dramatic increase in the prevalence and clinical impact of infections caused by bacteria 
producing carbapenemases is a global health concern. These carbapenemase-producing organisms 
(CPO) are especially problematic when encountered in members of the family Enterobacteriaceae. 
Due to their ability to readily spread and colonize patients in health care environments, preventing 
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the transmission of these organisms is a major public health initiative and coordinated 
international efforts are needed to contain the risk of infection. Central to the treatment and control 
of CPO are phenotypic- (growth-/biochemical-dependent) and nucleic acid-based carbapenemase 
detection tests that identify carbapenemase activity directly or their associated molecular 
determinants. Importantly, bacterial isolates harboring carbapenemases are often resistant to 
multiple antibiotic classes resulting in limited therapy options. Emerging agents, novel antibiotic 
combinations and treatment regimens offer promise for management of these infections. This 
review highlights our current understanding of CPO with emphasis on their epidemiology, 
detection, treatment, and control.
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Introduction
One of the most concerning forms of antimicrobial resistance (AMR) is resistance to the 
carbapenems, especially when observed in members of the family Enterobacteriaceae. A 
primary mechanism of carbapenem resistance in Gram-negative bacteria is acquired 
carbapenemases, enzymes that hydrolyze these antibiotics. In this review, the epidemiology, 
laboratory detection, approaches to combat widespread dissemination, and treatment 
strategies for carbapenemase-producing organisms (CPO), especially carbapenemase-
producing carbapenem-resistant Enterobacteriaceae (CP-CRE), will be discussed.
The Biology and Epidemiology of CPO
Phenotypic resistance to carbapenems in Gram-negative bacteria commonly results from 
acquisition of carbapenemases, or production of cephalosporinases combined with mutations 
that decrease permeability of the bacterial cell wall to entry of carbapenems. CPO may 
exhibit significant variation in carbapenem minimum inhibitory concentration (MIC) values 
depending on their permeability status, the rate of carbapenem hydrolysis by the associated 
enzyme, and the level of gene expression [1]. Carbapenemases belong to Ambler classes A, 
B, or D, with class A and D enzymes possessing a serine-based hydrolytic mechanism, and 
class B enzymes requiring one or two zinc ions for their catalytic activity [1]. There is a rare 
instance of class C beta-lactamase that can hydrolyze imipenem (CMY-10) [2]. Globally 
distributed in many genera of bacteria, certain carbapenemases are typically associated with 
specific regions or countries (Figure 1). However, in an era of widespread international 
travel and exposure to medical care, the association between a specific resistance mechanism 
and a given region or country may change, creating an urgent need for routine local and 
national surveillance.
The class A Klebsiella pneumoniae carbapenemase (KPC) has been extensively reported in 
K. pneumoniae and other Enterobacteriaceae, but has also been identified in other Gram-
negative pathogens including Pseudomonas aeruginosa [3]. KPC-producing K. pneumoniae 
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are widespread in the United States, but are also endemic in some European countries such 
as Greece and Italy (Figure 1) [4].
Class B beta-lactamases, or metallo-beta-lactamases (MBL), are commonly identified in 
Enterobacteriaceae and in P. aeruginosa [5]. Among the MBLs, New Delhi Metallo-beta-
lactamase (NDM)-, Verona Integron-encoded Metallo-beta-lactamase (VIM)-, and 
Imipenemase Metallo-beta-lactamase (IMP) enzymes, are the most frequently identified 
worldwide (Figure 1) [5]. IMP-producers are mainly detected in China, Japan, and Australia, 
mostly in Acinetobacter baumannii. VIM-producers are most often found in Italy and 
Greece (Enterobacteriaceae), and in Russia (P. aeruginosa) [6,7].
Acquired class D carbapenem-hydrolyzing beta-lactamases are commonly reported in A. 
baumannii (mainly OXA-23-, OXA-40-, and OXA-58-like enzymes), but not in P. 
aeruginosa. OXA-48 and derivatives (e.g., OXA-181 and OXA-232), have been detected in 
Enterobacteriaceae, hydrolyze narrow-spectrum beta-lactams and weakly hydrolyze 
carbapenems, but spare broad-spectrum cephalosporins [8]. OXA-48-producing 
Enterobacteriaceae have been endemic in Turkey since 2004, and are now also frequently 
discovered in several European countries (e.g., France and Belgium), and across North 
Africa (Figure 1) [9]. Ten variants of OXA-48 beta-lactamases are acknowledged and are 
increasingly reported worldwide [9], notably among nosocomial K. pneumoniae and 
community Escherichia coli isolates [10].
Carbapenemase genes are often located on mobile genetic elements further enhancing their 
spread. For example, the widespread dissemination of the blaOXA-48 gene was shown to be 
related to a successful and epidemic plasmid that conjugates at high rates within 
Enterobacteriaceae [11].
Other less common carbapenemases belonging to a variety of molecular classes (e.g., class 
A FRI-1 and IMI-like beta-lactamases, class B SPM-1 and GIM-1, and class D OXA-198) 
are reported sporadically and are found in specific species, likely because the corresponding 
genes are located on narrow host-range plasmids or chromosomes, which makes wide 
diffusion unlikely [10,12].
Laboratory Detection of CPO
Detection of carbapenemase-mediated carbapenem resistance is essential for patient 
management, infection control, and public health surveillance. The diversity of these 
enzymes and the range of associated susceptibility phenotypes makes detection challenging. 
Selection of a carbapenemase detection test (CDT) is contingent on several factors: 
epidemiology, diagnostic performance, labor intensity, complexity, and cost. The relative 
importance of turnaround time depends on whether the assay will be employed for 
therapeutic decision making and/or infection control or surveillance studies.
CDTs are broadly differentiated into two groups: phenotypic- (growth-/biochemical-
dependent) and nucleic acid-based. Phenotypic assays monitor carbapenemase activity 
through a variety of methods: growth of a susceptible reporter strain following drug 
inactivation by a carbapenemase-producing test strain, observation of a pH change after 
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beta-lactam ring hydrolysis, detection of carbapenem hydrolysis products, or via inhibition 
with small molecules. In contrast, nucleic acid assays detect genetic determinants associated 
with carbapenemases.
The modified Hodge test (MHT) is probably the most extensively described CDT used in 
Enterobacteriaceae. This assay demonstrates acceptable sensitivity for most 
carbapenemases, especially KPC enzymes, but low sensitivity for NDM-producing strains 
[13,14]. Additionally, it has poor specificity; isolates encoding cephalosporinases in 
conjunction with porin mutations often produce false-positive results [13,15]. While the 
MHT is inexpensive and uncomplicated to perform, it is often difficult to interpret and 
requires an additional 24-hour growth step after AST results are obtained.
Conceptually akin to the MHT, the carbapenem inactivation method (CIM) assesses growth 
of a susceptible reporter strain around a carbapenem disk previously incubated with a 
suspension of a suspected carbapenemase-producing test strain. If the test strain produces a 
carbapenemase, drug in the disk will be inactivated thus allowing growth of the reporter 
strain up to the edge of the disk, whereas a zone of growth inhibition indicates the antibiotic 
in the disk remains active, thus the test strain lacks carbapenemase activity. CIM sensitivity 
is reported to be between 98 and 100% [16,17], but again this technique requires an 
additional 24-hour culture step. A modified version of the CIM (mCIM) was evaluated in a 
multi-center study, demonstrating 97% sensitivity and 99% specificity for detection of 
carbapenemase production in Enterobacteriaceae [18]. Based on those data, the mCIM was 
added to the CLSI M100 document as a reliable method for detection of carbapenemase 
production in Enterobacteriaceae [19].
The Carba NP test (RAPIDEC® CARBA NP, bioMérieux, Durham, NC), its derivatives, and 
matrix-assisted laser desorption ionization-time of flight mass spectrometry (MALDI-TOF 
MS), monitor the hydrolysis of carbapenems using bacterial extracts [20,21] and produce 
same-day results. In the Carba NP test, carbapenemase-dependent hydrolysis of imipenem 
causes a decrease in pH, registered by a pH indicator as a color change. The test exhibits 
excellent sensitivity [20], although the recognition of OXA-48-producing isolates may be 
challenging [17,22]. To aid in early identification, the Carba NP test has been successfully 
extended to detect the presence of CPO in positive blood cultures even before isolation of 
organism on solid media, providing value for antibiotic stewardship [23].
MALDI-TOF MS can identify carbapenem degradation products following incubation of a 
bacterial protein extract with a carbapenem substrate. Overall, the sensitivity of MALDI-
TOF MS for this purpose is high, and sensitivity for OXA-48-producing isolates is enhanced 
by inclusion of bicarbonate in the reaction buffer [22]. Notwithstanding the promise of mass 
spectrometry-based assays, because they are complex to perform and interpret, widespread 
implementation in clinical microbiology laboratories may be unfeasible.
Conventional AST methods such as broth microdilution, disk diffusion, and gradient 
diffusion can be modified to detect different classes of carbapenemases by performing them 
in the absence and presence of small molecule inhibitors including phenylboronic acid, 
which inhibits serine active site enzymes, and ethylenediaminetetraacetic acid, an inhibitor 
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of MBL activity. These assays have reportedly high sensitivities and specificities 
[24,25,26,27,28], are inexpensive, and generally easy to implement and interpret but require 
overnight incubation.
Nucleic acid-based CDT include commercially available and laboratory-developed PCR and 
microarray platforms to detect carbapenemase genes in bacterial isolates or directly from 
clinical specimens. They exhibit clinically relevant sensitivities and specificities and have 
same-day turnaround times [29,30,31,32,33], but are typically associated with high costs. In 
the setting of changing epidemiology or emergence of novel enzymes, the specificity of 
targeted PCR- or microarray-based platforms could be a shortcoming.
Whole-genome sequencing (WGS) platforms potentially represent the ultimate molecular 
CDT by interrogating the entire genomic content, chromosomal and extrachromosomal, of a 
bacterium to identify carbapenem resistance determinants [34,35,36]. Furthermore, WGS 
data provide an opportunity to query for extra information, including strain relatedness, 
plasmid types encoding the carbapenemase, other factors influencing carbapenem resistance 
(e.g., porin mutations), presence of additional resistance factors, and data can be analyzed in 
near real-time or archived for future inquiry. Notwithstanding the power and promise of 
WGS, these assays are still the purview of advanced clinical microbiology and public health 
laboratories, and require considerable expertise to perform and interpret. As algorithms 
improve, costs decrease, and commercialized options are brought to market, the clinical 
workforce is likely to become increasingly proficient at performing and interpreting these 
data allowing WGS to gain wider acceptance.
WGS for Investigation of the Epidemiology and Diversity of CPO
Recent studies indicate that WGS, combined with hospital epidemiology, may facilitate the 
tracking of transmissions within healthcare facilities with the level of precision necessary to 
guide the modification of infection control procedures and limit the spread of healthcare-
associated infections [36,37,38,39]. One example is the National Institutes of Health Clinical 
Center outbreak in which a single patient colonized on admission with KPC-producing K. 
pneumoniae was eventually linked to CPO colonization in 18 additional patients. The 
epidemiologic data could not discriminate between undetected transmission from the index 
patient or introduction of a second strain. The extensive genetic similarity among KPC-
producing K. pneumoniae in the United States prevented a definitive match to the index 
patient using standard outbreak investigation tools such as pulsed-field gel electrophoresis or 
repetitive element PCR. WGS revealed direct linkage of the index patient, with transmission 
originating from three different anatomic sites [34], indicating silent colonization, even in 
immunocompromised patients. In another healthcare-related outbreak, WGS was 
instrumental in identifying limited healthcare-associated transmission of CRE against a 
background of sporadic introduction of multiple other strains [36]. In other studies, WGS 
was key in determining the phylogeny of carbapenem resistant Enterobacter species and how 
gene regulation by insertion sequence elements impacted carbapenem and multidrug 
resistance in A. baumannii [40,41]. WGS has also been used to create a reference set 
capturing the diversity of plasmids and mobile elements that carry the KPC gene [36,42].
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Novel Treatment Strategies for CPO
Treatment of CPO, especially CP-CRE, remains problematic. Patients with CP-CRE 
infection suffer unacceptably high mortality, emphasizing the need for novel diagnostics and 
therapies. Studies performed to date demonstrate a bias to report trials of successful 
combination chemotherapy, informed largely by results from in vitro studies. In most trials 
targeting CP-CRE, combination therapies have included the use of i) colistin (polymyxin E) 
and a carbapenem, ii) colistin and tigecycline, or colistin and fosfomycin, or iii) double 
carbapenem therapy. Interestingly, it was also shown in vitro that dual carbapenem 
combinations might work against carbapenemase-producing strains, with significant 
synergies observed when using imipenem and another carbapenem [43].
In an early study performed at a tertiary care center, Qureshi and colleagues reported that 
28-day mortality was 13.3% in the combination therapy group (colistin and another agent) 
compared with 57.8% in the monotherapy group (P= 0.01), and that combination regimens 
were independently associated with better survival (P=0.02) [44]. Additionally, a multi-
center retrospective cohort study conducted in three large Italian teaching hospitals 
examined death within 30 days of the first positive blood culture among 125 patients with 
blood stream infections caused by KPC-producing K. pneumoniae [45]. That investigation 
found 54.3% mortality in the monotherapy arm versus 34.1% mortality in the combination 
therapy group (P = 0.02); triple combination therapy (tigecycline, colistin, and meropenem) 
was associated with lowest mortality (P = 0.01). This study also revealed that patients 
infected by CP-CRE with imipenem MIC values of ≥4 μg/mL had worse outcomes than 
patients whose isolates had an MIC value of ≤2 μg/mL. The “dividing line” appears to be an 
MIC value between 2 and 4 μg/mL and predicted differences in mortality were notable 
(16.1% versus 76.9%; P <0.01); each imipenem MIC doubling dilution increased the 
probability of death two-fold.
In a subsequent review of 20 clinical studies involving 414 patients, Tzouvelekis and 
colleagues reported that a single active agent resulted in mortality rates not significantly 
different from those observed in patients administered no active therapy [46]. Consistent 
with the notions reported above, combination therapy with two or more agents active in vitro 
was superior to monotherapy, providing a clear survival benefit (mortality rate, 27.4% versus 
38.7%; P <0.001). The lowest mortality rate (18.8%) was observed in patients treated with 
carbapenem-containing combinations.
In contrast, Falagas and partners in 2014 reported the largest meta-analysis performed to 
date [47], examining 20 studies involving 692 patients. Surprisingly, the authors reported 
50% mortality in patients treated with tigecycline and gentamicin, 64% mortality for 
tigecycline and colistin, and 67% mortality for carbapenems and colistin. This 
comprehensive analysis called into question the conclusions drawn from the earlier 
retrospective, nonrandomized studies, and emphasized that unexplained molecular 
heterogeneity, and non-uniform microbiology testing might be confounding results. These 
differences suggest that studies concluding the superiority of combination therapy over 
monotherapy may not be sufficiently rigorous for us to accept their conclusions.
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What about new drugs in development? Avibactam is a synthetic non-beta-lactam, bicyclic 
diazabicyclooctane beta-lactamase inhibitor (DBO), that inhibits the activities of Ambler 
class A and C beta-lactamases and some Ambler class D enzymes. Avibactam closely 
resembles portions of the cephem bicyclic ring system, and has been shown to bond 
covalently to beta-lactamases. Against carbapenemase-producing K. pneumoniae, the 
addition of avibactam significantly improves the activity of ceftazidime in vitro (∼four-fold 
MIC reduction). In surveillance studies, the combination of ceftazidime with avibactam 
restores in vitro susceptibility against all ESBLs and most KPCs tested. Studies comparing 
outcomes of infections with KPC-producing Gram-negative bacteria treated with 
ceftazidime-avibactam as monotherapy or in combination with colistin are ongoing. An 
important study comparing the outcomes of patients infected with CRE treated with colistin 
vs. ceftazidime/avibactam was recently performed [48]. Patients initially treated with either 
ceftazidime-avibactam or colistin for CRE infections were selected from the Consortium on 
Resistance Against Carbapenems in Klebsiella and other Enterobacteriaceae (CRACKLE), a 
prospective, multicenter, observational study. Thirty-eight patients were treated first with 
ceftazidime-avibactam and 99 with colistin either as monotherapy or combination therapy. 
Patients treated with ceftazidime-avibactam vs colistin (monotherapy or combination) had a 
higher probability of a better outcome as compared to patients treated with colistin. This 
study strengthens the notion that treatment with a highly active agent as monotherapy in the 
appropriate clinical setting may be better than therapy with a less desirable agent singly or in 
combination.
Relebactam, also a DBO, combined with imipenem/cilistatin, will soon be evaluated in 
clinical studies [49]. In vitro studies indicate that imipenem/cilistatin-relebactam is 
comparable to ceftazidime-avibactam. The role of the combination of imipenem versus 
ceftazidime with different DBOs remains to be defined.
The United States Food and Drug Administration (FDA) recently approved ceftazidime-
avibactam based on data obtained in Phase II/III trials of complicated urinary tract infections 
and intra-abdominal infections (ceftazidime-avibactam combined with metronidazole). 
Despite encouraging results, the FDA cautioned that ceftazidime-avibactam should be 
reserved for situations when there are limited or no alternative drugs for treating an 
infection. The concern was that resistance to ceftazidime-avibactam would emerge in KPC-
producing strains. Regrettably resistance is already being reported due to mutations 
occurring in the KPC enzyme and porin changes [50,51]
In summary, combination chemotherapies seem to be effective against KPC-producing 
bacteria (Table 1) [49], but we still need to design the right trial to answer the fundamental 
question as to why. We also need to carefully examine new drugs in the pipeline, and use 
clinical trials to define their best use. Other drugs in development are summarized in Table 
2. The reader will note that there are some drugs specifically targeted for MBL producers 
(aztreonam/avibactam and cefidericol); these developments are awaited in earnest. Novel 
combinations (ceftazidime/avibactam paired with aztreonam) are also being explored [52]. 
In addition, optimizing pharmacokinetic and pharmacodynamic parameters are essential for 
ensuring efficacy in difficulty to treat infections. Activities such as testing in hollow fiber 
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models, prolonged or continuous infusion are being aggressively evaluated to optimize drug 
dosing [53,54,55].
Monitoring and Control of Carbapenemase-Producing Organisms
Approaches to addressing the rapid intercontinental spread of CPO and other multi-resistant 
organisms include surveillance and judicious use of infection prevention and control (IPC) 
practices. There is evidence that IPC efforts at the local and country-wide level are effective 
in reducing transmission of CPO [56], and the role of IPC in the overall control of CPO 
cannot be overemphasized. Regarding surveillance at a global level, the Global 
Antimicrobial Resistance Surveillance System (GLASS) program was launched in 2015 as 
part of the WHO Global Action Plan on AMR to support a standardized approach to 
collection, analysis, and sharing of AMR data to inform local and national decision-making, 
and provide the evidence base for action and advocacy. Another approach that has been 
suggested is the application of the International Health Regulations (IHR), which represents 
a legal framework for international efforts to reduce the risk from public health threats that 
may spread between countries [57]. IHR requires countries to report certain disease 
outbreaks, including smallpox, wild-type poliomyelitis, severe acute respiratory syndrome, 
new types of influenza, or any public health event of international concern (PHEIC) which 
may include “new or emerging antibiotic resistance” [57]. The rationale for declaring AMR, 
specifically CPO, as a PHEIC has been reported previously [58], and includes multi-drug 
resistance, propensity for rapid spread, absence of geographic/political boundaries, presence 
in E. coli (the most common cause of urinary tract infection globally), presence in microbes 
of high public health importance, namely Salmonella, Shigella, and Vibrio species, and 
carriage of resistance traits on very mobile broad-host range plasmids [59]. The emergence 
of plasmid-mediated colistin resistance in Enterobacteriaceae has created a potential 
scenario of pan-resistant CRE [60].
Although application of IHR to CPO may have potential benefits including increasing 
surveillance and response capacities to address the spread of AMR on a global basis [58], a 
counter reaction argues that it is difficult to appreciate how the global spread of AMR 
constitutes an “extraordinary event” and that it is neither pragmatic nor within the 
framework of the IHR to consider it a PHEIC [61]. The only PHEICs declared to date 
include H1N1 2009 global influenza pandemic, Ebola virus disease in 2014, and the recent 
clusters of microcephaly and neurological abnormalities associated with Zika virus. In 
addition to global efforts underway, country-specific guidelines, including The Combating 
Antibiotic Resistant Bacteria report and the President's Council of Advisors on Science and 
Technology strategic plans, provide practical recommendations to the United States 
government to facilitate addressing the problem of antimicrobial resistance. Canada and the 
European Union have made similar commitments.
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Summary
Infections caused by carbapenemase-producing bacteria have experienced unprecedented 
intercontinental spread and proliferation and continue to be a therapeutic challenge. The 
genetic features that facilitate widespread dissemination are becoming increasingly 
understood. Control requires efficient laboratory detection and treatment, and a 
coordinated international response.
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Figure 1. 
Worldwide distribution of carbapenemases. A) KPC producers in Enterobacteriaceae and P. 
aeruginosa. B) NDM producers in Enterobacteriaceae and P. aeruginosa. C) OXA-48 
producers in Enterobacteriaceae.
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Table 1
Clinical regimens used in observational studies for treating carbapenem-resistant Klebsiella pneumoniae 
where carbapenemase is identified [45].
Beta-lactamases present Regimen Improved survival versus 
monotherapy
KPC- and MBL- producing K. pneumoniae Carbapenem and tigecycline, plus aminoglycoside or colistin;
Carbapenem and tigecycline;
Carbapenem and aminoglycoside;
Carbapenem and colistin
Yes
KPC-producing K. pneumoniae Colistin and aminoglycoside;
Colistin and tigecycline;
Colistin and quinolone;
Colistin and carbapenem;
Carbapenem and carbapenem
Yes
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Table 2
Novel agents in development for treating carbapenem-resistant and CPO
Antibiotic Drug class Intended Indication/Activity/Comments
Cefiderocol Siderophore-β-lactam (cephalosporin)
Complicated urinary tract infections (cUTIs), carbapenem-
resistant Gram-negative bacterial infections
Active against metallo-beta-lactamase producing strains
ceftaroline fosamil/avibactam Cephalosporin and DBO BLI. Currently undefined.
Eravacycline Tetracycline cIAI and cUTIMulti-drug resistant organisms (MDRO)
Imipenem/cilistatin/relebactam Carbapenem and DBO beta-lactamase inhibitor (BLI).
cUTIs, intra-abdominal infections (cIAI), hospital acquired 
pneumonia (HAP)
Active against ESBLs and KPCs
Meropenem-vaborbactam Carbapenem and cyclic boronic acid beta-lactamase inhibitor
cUTI, catheter-related bloodstream infections, HAP/
ventilator-associated bacterial pneumonia (VAP), cIAI due to 
CRE
Plazomycin Aminoglycoside cUTI, catheter-related bloodstream infections, HAP/
ventilator-associated pneumonia, cIAI due to CPO and CRE
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